請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36123
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 詹東榮(Tong-Rong Jan) | |
dc.contributor.author | Shu-Ting Su | en |
dc.contributor.author | 蘇淑婷 | zh_TW |
dc.date.accessioned | 2021-06-13T07:51:51Z | - |
dc.date.available | 2008-07-28 | |
dc.date.copyright | 2005-07-28 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-25 | |
dc.identifier.citation | BACZYNSKY, W.O. & ZIMMERMAN, A.M. (1983a). Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. I. In vivo investigation of the primary and secondary immune response. Pharmacology, 26, 1-11.
BACZYNSKY, W.O. & ZIMMERMAN, A.M. (1983b). Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacology, 26, 12-9. BASSO, M.R. & BORNSTEIN, R.A. (2003). Effects of past noninjection drug abuse upon executive function and working memory in HIV infection. J Clin Exp Neuropsychol, 25, 893-903. CABRAL, G.A., STINNETT, A.L., BAILEY, J., ALI, S.F., PAULE, M.G., SCALLET, A.C. & SLIKKER, W., JR. (1991a). Chronic marijuana smoke alters alveolar macrophage morphology and protein expression. Pharmacol Biochem Behav, 40, 643-9. CABRAL, G.A. & VASQUEZ, R. (1991b). Effects of marijuana on macrophage function. Adv Exp Med Biol, 288, 93-105. CONDIE, R., HERRING, A., KOH, W.S., LEE, M. & KAMINSKI, N.E. (1996). Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem, 271, 13175-83. CONNOR, T.J. (2004). Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology, 111, 357-67. COSTA, B., COLLEONI, M., CONTI, S., PAROLARO, D., FRANKE, C., TROVATO, A.E. & GIAGNONI, G. (2004a). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol, 369, 294-9. COSTA, B., GIAGNONI, G., FRANKE, C., TROVATO, A.E. & COLLEONI, M. (2004b). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol, 143, 247-50. DAUL, C.B. & HEATH, R.G. (1975). The effect of chronic marihuana usage on the immunological status of rheusus monkeys. Life Sci, 17, 875-81. DVILANSKY, A., ZOLOTOV, Z., HERZLIKER, B. & NATHAN, I. (1984). Effects of ethanol, CBD and delta 'THC on proliferation of K-562 cells. Int J Tissue React, 6, 409-12. EL-GOHARY, M. & EID, M.A. (2004). Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum Exp Toxicol, 23, 149-56. FISCHER-STENGER, K., UPDEGROVE, A.W. & CABRAL, G.A. (1992). Delta 9-tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med, 200, 422-30. FRIEDMAN, H. & EISENSTEIN, T.K. (2004). Neurological basis of drug dependence and its effects on the immune system. J Neuroimmunol, 147, 106-8. GALLILY, R., EVEN-CHENA, T., KATZAVIAN, G., LEHMANN, D., DAGAN, A. & MECHOULAM, R. (2003). Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. Leuk Lymphoma, 44, 1767-73. GORTER, R. (1998). Cannabis and cannabidiol: interview with Robert Gorter, M.D. Interview by Fred Gardner. AIDS Treat News, 4-6 concl. HAYAKAWA, K., MISHIMA, K., ABE, K., HASEBE, N., TAKAMATSU, F., YASUDA, H., IKEDA, T., INUI, K., EGASHIRA, N., IWASAKI, K. & FUJIWARA, M. (2004). Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport, 15, 2381-5. IUVONE, T., ESPOSITO, G., ESPOSITO, R., SANTAMARIA, R., DI ROSA, M. & IZZO, A.A. (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem, 89, 134-41. IZZO, A.A. (2004). Cannabinoids and intestinal motility: welcome to CB2 receptors. Br J Pharmacol, 142, 1201-2. JAN, T.R., FARRAJ, A.K., HARKEMA, J.R. & KAMINSKI, N.E. (2003). Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol Appl Pharmacol, 188, 24-35. JAN, T.R., RAO, G.K. & KAMINSKI, N.E. (2002). Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol Pharmacol, 61, 446-54. JEON, Y.J., YANG, K.H., PULASKI, J.T. & KAMINSKI, N.E. (1996). Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol, 50, 334-41. KAPLAN, B.L., OUYANG, Y., ROCKWELL, C.E., RAO, G.K. & KAMINSKI, N.E. (2005). 2-Arachidonoyl-glycerol suppresses interferon-{gamma} production in phorbol ester/ionomycin-activated mouse splenoctyes independent of CB1 or CB2. J Leukoc Biol. KAPLAN, B.L., ROCKWELL, C.E. & KAMINSKI, N.E. (2003). Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther, 306, 1077-85. KLEIN, T.W., FRIEDMAN, H. & SPECTER, S. (1998a). Marijuana, immunity and infection. J Neuroimmunol, 83, 102-15. KLEIN, T.W., KAWAKAMI, Y., NEWTON, C. & FRIEDMAN, H. (1991). Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health, 32, 465-77. KLEIN, T.W., NEWTON, C. & FRIEDMAN, H. (1998b). Cannabinoid receptors and immunity. Immunol Today, 19, 373-81. KLEIN, T.W., NEWTON, C., ZHU, W., DAAKA, Y. & FRIEDMAN, H. (1995). delta 9-Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med, 209, 205-12. KRAFT, B. & KRESS, H.G. (2004). [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz, 18, 203-10. KUSHER, D.I., DAWSON, L.O., TAYLOR, A.C. & DJEU, J.Y. (1994). Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell Immunol, 154, 99-108. LODZKI, M., GODIN, B., RAKOU, L., MECHOULAM, R., GALLILY, R. & TOUITOU, E. (2003). Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release, 93, 377-87. MANN, P.E., COHEN, A.B., FINLEY, T.N. & LADMAN, A.J. (1971). Alveolar macrophages. Structural and functional differences between nonsmokers and smokers of marijuana and tobacco. Lab Invest, 25, 111-20. MASSI, P., VACCANI, A., CERUTI, S., COLOMBO, A., ABBRACCHIO, M.P. & PAROLARO, D. (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther, 308, 838-45. MCCARTHY, L., WETZEL, M., SLIKER, J.K., EISENSTEIN, T.K. & ROGERS, T.J. (2001). Opioids, opioid receptors, and the immune response. Drug Alcohol Depend, 62, 111-23. MCKALLIP, R.J., LOMBARD, C., MARTIN, B.R., NAGARKATTI, M. & NAGARKATTI, P.S. (2002). Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther, 302, 451-65. MCQUEEN, D.S., BOND, S.M., SMITH, P.J., BALALI-MOOD, K. & SMART, D. (2004). Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. Eur J Pharmacol, 491, 181-9. MECHOULAM, R., PARKER, L.A. & GALLILY, R. (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol, 42, 11S-19S. MISHIMA, K., HAYAKAWA, K., ABE, K., IKEDA, T., EGASHIRA, N., IWASAKI, K. & FUJIWARA, M. (2005). Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke, 36, 1077-82. MISHKIN, E.M. & CABRAL, G.A. (1985). delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J Gen Virol, 66 (Pt 12), 2539-49. MOORE, K.W., O'GARRA, A., DE WAAL MALEFYT, R., VIEIRA, P. & MOSMANN, T.R. (1993). Interleukin-10. Annu Rev Immunol, 11, 165-90. MORAHAN, P.S., KLYKKEN, P.C., SMITH, S.H., HARRIS, L.S. & MUNSON, A.E. (1979). Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun, 23, 670-4. MOREIRA, F.A. & GUIMARAES, F.S. (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol, 512, 199-205. MOSMANN, T.R. & SAD, S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today, 17, 138-46. NAHAS, G., ARMAND, J.P. & HSU, J. (1974). [In vitro inhibition of the blastogenesis of T lymphocytes by delta 9 tetrahydrocannabinol]. C R Acad Sci Hebd Seances Acad Sci D, 278, 679-80. NEWTON, C.A., KLEIN, T.W. & FRIEDMAN, H. (1994). Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun, 62, 4015-20. PATEL, V., BORYSENKO, M., KUMAR, M.S. & MILLARD, W.J. (1985). Effects of acute and subchronic delta 9-tetrahydrocannabinol administration on the plasma catecholamine, beta-endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proc Soc Exp Biol Med, 180, 400-4. PERTWEE, R.G. & ROSS, R.A. (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids, 66, 101-21. PETER, M.E. & KRAMMER, P.H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ, 10, 26-35. PETERSEN, B.H., GRAHAM, J. & LEMBERGER, L. (1976). Marihuana, tetrahydrocannabinol and T-cell function. Life Sci, 19, 395-400. PILLAI, R., NAIR, B.S. & WATSON, R.R. (1991). AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch Toxicol, 65, 609-17. PROSS, S.H., KLEIN, T.W., NEWTON, C.A., SMITH, J., WIDEN, R. & FRIEDMAN, H. (1990). Differential suppression of T-cell subpopulations by thc (delta-9-tetrahydrocannabinol). Int J Immunopharmacol, 12, 539-44. RAZDAN, R.K. (1986). Structure-activity relationships in cannabinoids. Pharmacol Rev, 38, 75-149. SACERDOTE, P., MARTUCCI, C., VACCANI, A., BARISELLI, F., PANERAI, A.E., COLOMBO, A., PAROLARO, D. & MASSI, P. (2005). The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol, 159, 97-105. SCHWARZ, H., BLANCO, F.J. & LOTZ, M. (1994). Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol, 55, 107-15. SRIVASTAVA, M.D., SRIVASTAVA, B.I. & BROUHARD, B. (1998). Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology, 40, 179-85. STRAUS, S.E. (2000). Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. Proc Natl Acad Sci U S A, 97, 9363-4. SUMARIWALLA, P.F., GALLILY, R., TCHILIBON, S., FRIDE, E., MECHOULAM, R. & FELDMANN, M. (2004). A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum, 50, 985-98. VACCANI, A., MASSI, P., COLOMBO, A., RUBINO, T. & PAROLARO, D. (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol, 144, 1032-6. VAN LOO, G., SAELENS, X., VAN GURP, M., MACFARLANE, M., MARTIN, S.J. & VANDENABEELE, P. (2002). The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ, 9, 1031-42. WATZL, B., SCUDERI, P. & WATSON, R.R. (1991). Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol, 13, 1091-7. YEA, S.S., YANG, K.H. & KAMINSKI, N.E. (2000). Role of nuclear factor of activated T-cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther, 292, 597-605. YUAN, M., KIERTSCHER, S.M., CHENG, Q., ZOUMALAN, R., TASHKIN, D.P. & ROTH, M.D. (2002). Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol, 133, 124-31. ZHU, W., FRIEDMAN, H. & KLEIN, T.W. (1998). Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J Pharmacol Exp Ther, 286, 1103-9. ZIMMERMAN, S., ZIMMERMAN, A.M., CAMERON, I.L. & LAURENCE, H.L. (1977). delta1-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacology, 15, 10-23. ZURIER, R.B., ROSSETTI, R.G., LANE, J.H., GOLDBERG, J.M., HUNTER, S.A. & BURSTEIN, S.H. (1998). Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum, 41, 163-70. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36123 | - |
dc.description.abstract | 大麻是一個被廣泛濫用的毒品,其主要成份為結構類似的大麻生物鹼(cannabinoids)。其中含量較豐富的有四氫大麻酚(Δ9-tetrahydrocannabinol;THC),是大麻中樞活性的主要成份;另一成分大麻二酚(cannabidiol;CBD)則是不具中樞活性的主要成份。許多文獻均指出大麻具有明顯的免疫調節作用,影響包括in vivo 及in vitro的各種免疫反應。其中THC的作用已有大量的文獻報告。近年來CBD的研究逐漸受到重視,相關研究指出CBD具有許多藥理活性,包括抗痙攣、抗氧化、抗發炎、保護神經、改善關節炎的症狀以及抗化療的嘔吐等,顯示CBD是大麻生物鹼中一個頗具應用潛力的大麻天然成分。然而,CBD是否對免疫系統具有免疫毒性,文獻報告稀少。因此,本論文主旨在探討CBD對動物體抗體生成反應之免疫毒理學研究。
在本論文中,以卵蛋白(Ova)專一性抗體的生成反應,來觀察CBD對動物整體性的免疫調節作用。結果顯示,小鼠給予單一劑量的CBD對Ova專一性抗體生成反應呈現劑量相關性的抑制作用,在低劑量CBD(5 mg/kg)即有顯著的抑制效果。連續五天,每天一次個別給予腹腔注射CBD(5或20 mg/kg),結果也發現多重高劑量的CBD(20 mg/kg)具有顯著抑制Ova專一性抗體生成反應的作用。分析CBD抑制抗體生成反應的可能作用機制,結果顯示不論是in vivo或是in vitro投與CBD,皆對脾臟細胞分泌IL-2、IL-4和IFN-γ以及細胞的增生和代謝活性具一致性的抑制作用。但以ribonuclease protection assay (RPA)或RT-PCR分析細胞激素mRNA的表現,則沒有觀察到任何影響。顯示細胞激素的受抑制可能不是直接經由干擾細胞激素基因的表現。進一步探討CBD是否誘發脾臟細胞的凋亡反應,發現脾臟細胞以CBD處理6小時,代表凋亡後期的annexin V及propidium iodide陽性族群的細胞比率明顯上升,且CBD誘發脾臟細胞發生凋亡的作用呈現濃度相關性和時間相關性,接受CBD處理的細胞也出現凋亡反應典型的DNA laddering現象。進一步以RPA分析bcl family 調節細胞凋亡因子mRNA在脾臟細胞的表現情形,結果顯示CBD增加bak和bax等促進凋亡因子mRNA的表現。 綜合本論文的實驗結果,CBD的可能作用機制是經由促進bak和bax的表現而誘發脾臟細胞發生凋亡,導致脾臟細胞活性的下降,造成IL-2、IL-4和IFN-γ等細胞激素分泌的減少,進而導致抗體生成反應受到抑制。本論文的研究結果顯示不具中樞活性的CBD對動物體的抗原專一性抗體生成反應和T細胞活性具有顯著的免疫毒性作用。 | zh_TW |
dc.description.abstract | Marijuana is one of the commonly abused drugs worldwide. The primary active components of marijuana are cannabinoids, such as Δ9-tetrahydrocannabinol (THC) which is psychoactive. In contrast to THC, cannabidiol (CBD) is another abundant cannabinoid that is nonpsychroactive. A line of evidence indicates that THC exhibits profound immunomodulatory activities in a variety of in vivo and in vitro experimental systems. Recently, a number of pharmacological activities possessed by CBD have been reported, including anticonvulsive, anxiolytic, antipsychotic, neuroprotective, antinausea and antirheumatoid effects. Thus, the potential pharmacological application and toxicity of CBD deserve further investigation. In light of the widely demonstrated immunomodulatory properties of cannabinoid compounds, the objective of the present studies was to investigate the effects of CBD on the immune system.
The results demonstrated that administration of ovalbumin (Ova)-immunized BALB/c mice with single dose of CBD (5-20 mg/kg) markedly suppressed the serum concentrations of Ova-specific immunoglobulins in a dose dependent manner. Five consecutive daily injections of mice with the high dose of CBD (20 mg/kg) also produced the same inhibitory effect, whereas low dose of CBD (5 mg/kg) did not. To elucidate the possible underlying mechanisms by which CBD suppressed antibody production, the effects of CBD on cytokine secretion, proliferation and metabolic activity of splenocytes were examined. Both in vivo and in vitro treatment of splenocytes with CBD significantly inhibited IL-2, IL-4 and IFN-γ secretion, concanavalin A-induced proliferation, and metabolic activity of splenocytes. However, the expression of cytokine mRNA was not influenced by CBD treatment, suggesting that CBD-induced inhibition of cytokine secretion is not mediated directly by the suppression of cytokine gene expression. As splenocyte proliferation and metabolic activity were suppressed by CBD, the present studies investigated whether CBD could induce apoptosis of splenocytes. The results of flow cytometric analysis demonstrated that CBD increased the population of splenocytes that were double positive with annexin V and propidium iodide, indicating the induction of late apoptotic responses of cells by CBD. Furthermore, typical DNA laddering was observed in splenocytes treated with CBD. Further mechanistic studies showed the increased mRNA expression of bak and bax in CBD-treated splenocytes. Collectively, results of the present studies demonstrated the immunotoxicity of CBD in vivo and in vitro. CBD suppressed the antibody production by Ova-immunized mice, that is mediated, at least in part, by the inhibition of T-cell functions. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T07:51:51Z (GMT). No. of bitstreams: 1 ntu-94-R91629023-1.pdf: 1901255 bytes, checksum: 6ba0977c4d2fe6167c375290f66c837c (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 中文摘要
英文摘要 縮寫檢索表 目錄 圖次 第一章、序論................................. 12 第一節、藥物濫用 12 第二節、藥物濫用對免疫系統的影響............. 13 第二章、文獻探討............................. 14 第一節、大麻簡介............................. 14 第二節、大麻對免疫系統的影響................. 15 第三節、T細胞在免疫系統中扮演的角色......... 19 第四節、免疫球蛋白(immunoglobumin;Ig)的種類和細胞激素之關係........................................... 19 第五節、細胞凋亡(apoptosis).................. 20 第三章、實驗目的............................. 22 第四章、實驗材料與方法....................... 23 第一節、實驗材料............................. 23 第二節、實驗方法............................. 25 一、實驗設計與流程........................... 25 1、In vivo 活體動物模式實驗:................ 25 A、 CBD對小鼠抗體生成作用之實驗模式..... 25 B、 急性單一劑量CBD處理小鼠之脾臟細胞製備........................................... 27 2、In vitro 離體細胞培養模式實驗............. 28 A、CBD處理對離體脾臟細胞之影響實驗模式....... 28 B、拮抗劑(antagonist)與CBD對離體脾臟細胞之實驗模式........................................... 30 二、實驗方法................................. 31 1、酵素連結免疫螢光分析法 (enzyme linked immunosorbent assay;ELISA)................................ 31 2、萃取脾臟細胞total RNA..................... 31 3、反轉錄酶-聚合酶鏈反應(reverse transctription-polymerase chain reaction;RT-PCR)........... 32 4、RNase protection assay (RPA).............. 32 5、DNA萃取及DNA fragmentation分析............ 33 第五章、實驗結果............................. 34 第一節、CBD對小鼠抗體生成反應之影響.......... 34 一、單一劑量CBD對抗體生成之影響.............. 34 二、多重劑量CBD對抗體生成之影響.............. 34 第二節、單一劑量CBD對小鼠脾臟細胞活性之影響.. 35 一、單一劑量CBD對小鼠脾臟細胞分泌細胞激素之影響........................................... 35 二、單一劑量CBD對小鼠脾臟細胞增生反應之影響.. 35 三、單一劑量CBD對小鼠脾臟細胞表現細胞激素mRNA之影響........................................... 36 第三節、CBD對離體脾臟細胞活性之影響.......... 36 一、CBD對離體脾臟細胞分泌細胞激素之影響...... 36 二、CBD對離體脾臟細胞增生反應之影響.......... 36 三、CBD對離體脾臟細胞表現細胞激素mRNA之影響.. 37 四、CBD對離體脾臟細胞凋亡之影響.............. 37 五、CBD誘發離體脾臟細胞DNA fragmentation之作用........................................... 37 六、CBD對離體脾臟細胞表現細胞凋亡因子mRNA之影響........................................... 38 七、拮抗劑(antagonists)對CBD抑制脾臟細胞IL-2分泌和誘發凋亡反應之影響................................... 38 第六章、討論................................. 59 第七章、參考文獻............................. 64 | |
dc.language.iso | zh-TW | |
dc.title | 大麻二酚(Cannabidiol)對抗體生成反應和T細胞活化與凋亡之影響 | zh_TW |
dc.title | The effect of cannabidiol on antibody production and T-cell activation and apoptosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李志恆(Jih-Heng Li),龐飛(Fei Pang),魏孝萍(Shiaw-Pyng Wey) | |
dc.subject.keyword | 大麻,免疫,細胞凋亡, | zh_TW |
dc.subject.keyword | cannabidiol,immune system,apoptosis, | en |
dc.relation.page | 68 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-07-25 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 1.86 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。